Skip to main content

Best Healthcare ETFs in Canada (2026)

Updated

If you want the broader ETF framework before adding a healthcare tilt, start with our ETFs and index funds hub.

Key takeaways:

  • Canada lacks pure-play healthcare stocks due to universal government healthcare — most exposure comes from US or global ETFs.
  • XHC (TSX) is the most popular Canadian-listed healthcare ETF with 0.72% MER.
  • VHT and XLV (US-listed) offer much lower MERs (0.09-0.10%) but require USD conversion.
  • HHL (TSX) uses a covered call strategy for ~7.5% yield — popular with income investors.
  • Healthcare is a defensive sector benefiting from aging demographics and GLP-1 drug innovation.
  • Hold US-listed healthcare ETFs in RRSP to avoid US dividend withholding tax.

Best Healthcare ETFs Listed on the TSX

ETF Ticker MER Yield Holdings Distribution Strategy
iShares Global Healthcare XHC 0.72% ~1.0% 100+ Semi-annual Global healthcare (US-heavy)
Harvest Healthcare Leaders Income HHL 0.45% ~7.5% 20 Monthly Top healthcare, covered call overlay
TD Global Healthcare Leaders THC 0.65% ~0.5% 30+ Annual Actively managed global healthcare
Evolve Global Healthcare Enhanced Yield LIFE 0.45% ~6.0% 20 Monthly Healthcare leaders, covered call

Best US-Listed Healthcare ETFs (Accessible from Canada)

If you plan to buy the US-listed versions, pair this page with best account type for US stocks and ETFs in Canada and Norbert’s Gambit.

ETF Ticker MER Yield Holdings AUM Focus
Vanguard Health Care VHT 0.10% ~1.3% 400+ $18B+ Broad US healthcare
Health Care Select Sector SPDR XLV 0.09% ~1.5% 60 $40B+ S&P 500 healthcare
iShares Biotechnology IBB 0.44% ~0.2% 250+ $7B+ Biotech focused
iShares Global Healthcare IXJ 0.40% ~1.5% 100+ $5B+ Global healthcare
ARK Genomic Revolution ARKG 0.75% 0% 30+ $2B+ Genomics and biotech innovation
SPDR S&P Biotech XBI 0.35% ~0.5% 140+ $6B+ Equal-weight biotech

Healthcare Sector Breakdown

Sub-Sectors Within Healthcare ETFs

Sub-Sector Weight (Typical) Examples Growth Driver
Pharmaceuticals 25–30% Eli Lilly, Pfizer, Merck Drug pipelines, patent portfolios
Healthcare equipment 15–20% Abbott, Medtronic, Stryker Medical device innovation
Managed care 15–20% UnitedHealth, Elevance, Cigna US insurance market
Biotechnology 15–20% Amgen, Gilead, Regeneron Gene therapy, oncology
Life sciences tools 10–15% Thermo Fisher, Danaher Lab equipment, genomics
Healthcare facilities 5–10% HCA Healthcare Hospital networks

Top Holdings in Global Healthcare ETFs

Company Ticker Sub-Sector Weight (XHC) Market Cap
Eli Lilly LLY Pharma — GLP-1 drugs ~10% $800B+
UnitedHealth Group UNH Managed care ~8% $500B+
Johnson & Johnson JNJ Diversified healthcare ~6% $400B+
AbbVie ABBV Pharma — immunology ~5% $350B+
Novo Nordisk NVO Pharma — GLP-1 drugs (Danish) ~5% $400B+
Merck MRK Pharma — oncology ~4% $300B+
Thermo Fisher Scientific TMO Life sciences tools ~3% $200B+
Abbott Laboratories ABT Medical devices, diagnostics ~3% $200B+
Pfizer PFE Pharma ~2% $150B+
Amgen AMGN Biotech ~2% $150B+

Canadian Healthcare Stocks

Limited pure-play options available on the TSX:

Company Ticker Sub-Sector Market Cap Notes
Bausch Health BHC Pharma $5B+ Restructuring, high debt
Jamieson Wellness JWEL Consumer health $2B+ Vitamins and supplements
CannTrust / cannabis Various Cannabis Varies Not traditional healthcare
Neighbourly Pharmacy NBLY Pharmacy retail $500M+ Community pharmacies
Well Health Technologies WELL Health tech $1B+ Digital clinics

Most Canadians get healthcare exposure through global/US ETFs rather than domestic stocks.

Healthcare ETF Performance Comparison

ETF 1-Year 3-Year (Annualized) 5-Year (Annualized) MER
VHT (US healthcare) ~8% ~5% ~10% 0.10%
XLV (S&P 500 healthcare) ~10% ~6% ~11% 0.09%
XHC (Global healthcare, TSX) ~7% ~4% ~8% 0.72%
IBB (Biotech) ~5% ~2% ~6% 0.44%
HHL (Covered call) ~12% ~8% ~9% 0.45%

Past performance does not guarantee future results.

Why Healthcare Is a Long-Term Growth Sector

That is why healthcare often works better as a sector tilt inside a growth portfolio than as a standalone portfolio replacement. Compare best growth ETFs in Canada.

Driver Detail
Aging population Global 65+ population doubles by 2050 — healthcare spending increases with age
Innovation GLP-1 drugs, gene therapy, AI diagnostics, robotic surgery
Inelastic demand People need healthcare regardless of economy — defensive sector
Emerging markets Healthcare spending rising rapidly in developing countries
Obesity drugs GLP-1 market projected to exceed $100B by 2030
Government spending Healthcare is the largest government expenditure in most countries

Risks

Risk Detail
Drug pricing regulation US, Canada, EU may cap prices — compressing pharma margins
Patent cliffs Brand-name drugs lose exclusivity — revenue drops when generics enter
Clinical trial failures Biotech companies can crash on single trial failure
Political risk Elections and policy changes affect healthcare policy unpredictably
Concentration Top 10 holdings often represent 50%+ of capitalization-weighted ETFs
US-centric Most healthcare ETFs are 60–70% US companies
Higher MER (TSX-listed) Canadian-listed healthcare ETFs charge 0.45–0.72%, vs 0.09–0.10% US-listed

Portfolio Allocation

Investor Profile Healthcare Allocation Suggested ETF
Core index holder (already owns XEQT) 0% (already included) N/A — ~10% healthcare in XEQT
Wants sector tilt 5–10% XHC or VHT
Income-focused 5–10% HHL or LIFE
Aggressive growth 5–10% (biotech tilt) IBB or XBI

Tax Optimization

Account Best For
RRSP US-listed ETFs (VHT, XLV, IBB) — no US dividend withholding
TFSA Canadian-listed (XHC, HHL) — avoid US withholding tax
Non-registered Either — US withholding recoverable via foreign tax credit

For the treaty logic behind that account choice, see US dividend withholding tax in RRSP Canada and US dividend withholding tax in TFSA Canada.